Cartesian Therapeutics, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Cartesian Therapeutics, Inc. (RNAC) reported Revenue from Contract with Customer, Excluding Assessed Tax of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- Cartesian Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $0.00.
- Cartesian Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Cartesian Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $0.00.
- Cartesian Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $0.00.
- Cartesian Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $400.00K, a 98.95% decline from fiscal 2024.
- Cartesian Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $38.27M, a 47.19% increase from fiscal 2023.
- Cartesian Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $26.00M, a 76.53% decline from fiscal 2022.
- Cartesian Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $110.78M, a 30.21% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-04-30 | $0.00 derived: sum of 2 quarters · filed 2026-04-30 | $0.00 derived: sum of 3 quarters · filed 2026-04-30 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $400.00K 10-K · filed 2026-03-09 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $400.00K 10-Q · filed 2025-11-06 | -$436.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | $400.00K 10-Q · filed 2026-08-06 | -$436.00K derived: sum of 3 quarters · filed 2026-08-06 | -$436.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $400.00K 10-Q · filed 2026-04-30 | -$436.00K derived: sum of 2 quarters · filed 2026-04-30 | -$436.00K derived: sum of 3 quarters · filed 2026-04-30 | $32.84M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$836.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$836.00K derived: sum of 2 quarters · filed 2026-03-09 | $32.44M derived: sum of 3 quarters · filed 2026-03-09 | $38.27M 10-K · filed 2026-03-09 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $33.27M derived: sum of 2 quarters · filed 2025-11-06 | $39.11M 10-Q · filed 2025-11-06 | $47.38M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $33.27M 10-Q · filed 2025-08-07 | $39.11M 10-Q · filed 2025-08-07 | $47.38M derived: sum of 3 quarters · filed 2025-08-07 | $53.93M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $5.84M 10-Q · filed 2025-05-08 | $14.11M derived: sum of 2 quarters · filed 2025-05-08 | $20.66M derived: sum of 3 quarters · filed 2025-05-08 | $25.91M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $8.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $14.82M derived: sum of 2 quarters · filed 2025-03-13 | $20.07M derived: sum of 3 quarters · filed 2025-03-13 | $26.00M 10-K · filed 2025-03-13 |
| 2023-09-30 | $6.55M 10-Q · filed 2024-11-07 | $11.80M derived: sum of 2 quarters · filed 2024-11-07 | $17.74M 10-Q · filed 2024-11-07 | $34.53M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $5.25M 10-Q · filed 2024-08-08 | $11.19M 10-Q · filed 2024-08-08 | $27.98M derived: sum of 3 quarters · filed 2024-08-08 | $48.69M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $5.94M 10-Q · filed 2024-05-08 | $22.73M derived: sum of 2 quarters · filed 2024-05-08 | $43.44M derived: sum of 3 quarters · filed 2024-05-08 | $82.72M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $16.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $37.51M derived: sum of 2 quarters · filed 2024-03-07 | $76.78M derived: sum of 3 quarters · filed 2024-03-07 | $110.78M 10-K · filed 2024-03-07 |
| 2022-09-30 | $20.71M 10-Q · filed 2023-11-13 | $59.98M derived: sum of 2 quarters · filed 2023-11-13 | $93.98M 10-Q · filed 2023-11-13 | $123.92M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | $39.27M 10-Q · filed 2023-08-17 | $73.27M 10-Q · filed 2023-08-17 | $103.21M derived: sum of 3 quarters · filed 2024-03-07 | $127.64M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | $34.00M 10-Q · filed 2023-05-04 | $63.94M derived: sum of 2 quarters · filed 2024-03-07 | $88.36M derived: sum of 3 quarters · filed 2024-03-07 | $108.03M derived: sum of 4 quarters · filed 2024-03-07 |
| 2021-12-31 | $29.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $54.36M derived: sum of 2 quarters · filed 2024-03-07 | $74.03M derived: sum of 3 quarters · filed 2024-03-07 | $85.08M 10-K · filed 2024-03-07 |
| 2021-09-30 | $24.43M 10-Q · filed 2022-11-03 | $44.09M derived: sum of 2 quarters · filed 2022-11-03 | $55.14M 10-Q · filed 2022-11-03 | $67.09M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $19.66M 10-Q · filed 2022-08-08 | $30.71M 10-Q · filed 2022-08-08 | $42.66M derived: sum of 3 quarters · filed 2023-03-02 | $47.31M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $11.05M 10-Q · filed 2022-05-05 | $23.00M derived: sum of 2 quarters · filed 2023-03-02 | $27.65M derived: sum of 3 quarters · filed 2023-03-02 | $27.65M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | $11.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $16.60M derived: sum of 2 quarters · filed 2023-03-02 | $16.60M derived: sum of 3 quarters · filed 2023-03-02 | $16.60M 10-K · filed 2023-03-02 |
| 2020-09-30 | $4.65M 10-Q · filed 2021-11-09 | $4.65M derived: sum of 2 quarters · filed 2021-11-09 | $4.65M 10-Q · filed 2021-11-09 | $11.30M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | $6.65M derived: sum of 3 quarters · filed 2021-08-12 | $6.65M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-13 | $6.65M derived: sum of 2 quarters · filed 2021-05-13 | $6.65M derived: sum of 3 quarters · filed 2021-05-13 | $6.67M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $6.65M 10-K · filed 2020-03-12 | $6.65M derived: sum of 2 quarters · filed 2020-11-05 | $6.67M derived: sum of 3 quarters · filed 2020-11-05 | $6.68M 10-K · filed 2022-03-10 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 | $13.00K derived: sum of 2 quarters · filed 2020-11-05 | $23.00K 10-Q · filed 2020-11-05 | $926.00K derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $13.00K 10-Q · filed 2020-08-06 | $23.00K 10-Q · filed 2020-08-06 | $926.00K derived: sum of 3 quarters · filed 2020-08-06 | $926.00K derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $10.00K 10-Q · filed 2020-05-07 | $913.00K derived: sum of 2 quarters · filed 2020-05-07 | $913.00K derived: sum of 3 quarters · filed 2020-05-07 | $913.00K derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $903.00K 10-K · filed 2020-03-12 | $903.00K derived: sum of 2 quarters · filed 2020-03-12 | $903.00K derived: sum of 3 quarters · filed 2020-03-12 | $903.00K 10-K · filed 2021-03-12 |
| 2018-09-30 | $0.00 10-K · filed 2020-03-12 | $0.00 derived: sum of 2 quarters · filed 2020-03-12 | $0.00 10-Q · filed 2019-11-08 | $17.00K derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $0.00 10-K · filed 2020-03-12 | $0.00 10-Q · filed 2019-08-08 | $17.00K derived: sum of 3 quarters · filed 2020-03-12 | $44.00K derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $0.00 10-K · filed 2020-03-12 | $17.00K derived: sum of 2 quarters · filed 2020-03-12 | $44.00K derived: sum of 3 quarters · filed 2020-03-12 | $70.00K derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $17.00K 10-K · filed 2019-03-15 | $44.00K derived: sum of 2 quarters · filed 2019-03-15 | $70.00K derived: sum of 3 quarters · filed 2019-03-15 | $207.00K 10-K · filed 2020-03-12 |
| 2017-09-30 | $27.00K 10-K · filed 2019-03-15 | $53.00K derived: sum of 2 quarters · filed 2019-03-15 | $190.00K 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $26.00K 10-K · filed 2019-03-15 | $163.00K 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | $137.00K 10-K · filed 2019-03-15 | |||
| 2016-12-31 | $8.08M 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |